Rafaèle Tordjman, MD, PhD, is a venture capitalist with more than 15 years of experience, specialized in life sciences investments. She joined Sofinnova Partners in 2001, an independent venture capital firm based in Paris, and served as a Managing Partner until February 2017. Prior to this, she worked as a research scientist at the Institut National de la Recherche Médicale (INSERM) in Cochin Hospital, Paris. Before joining INSERM, she was a medical doctor specializing in clinical haematology and internal medicine. She obtained her PhD, with high honours, in haematopoiesis and angiogenesis from the University Paris VII followed by a post-doctoral fellowship in immunology. Rafaèle obtained her medical degree and her specialization in Haematology and Internal Medicine as a five-year fellow in Paris University Hospitals. She also participated in the “Young Manager Program” at INSEAD (France, in 2002). She has invested in and is on the board of Nucana Biomed and ObsEva [OBSV] – which went public on Nasdaq. She has also invested in and was on the board of Enyo Pharma, MedDay, Ascendis [ASDN] – listed on Nasdaq, Lysogene [LYS] – listed on Euronext Paris, DBV technologies[DBV] – listed on Nasdaq and EuroNext, Flexion Therapeutics [FLXN] – listed on Nasdaq, Corevalve before it was sold to Medtronic, Endoart before it was successfully sold to Allergan Inc, of Preglem before the latter was successfully sold to Gedeon Richter, and HBI Ltd before being acquired by Meda.
Rafaèle is also founder and Chairman of the not for profit association for promoting innovative healthcare driven by women, W.I.T.H (Women Innovating Together in Healthcare – http://with-association.com/).